DOI: https://doi.org/10.22263/2312-4156.2025.1.18
T.H. Hardziyevich, A.V. Ishchanka
New potential biomarkers in predicting the risk of developing COPD (literature review)
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2025;24(1):18-25.
Abstract.
COPD is considered a global problem, predicted to become the third leading cause of death and the fifth leading cause of disease by 2030. The impact of COPD, both diagnosed and undiagnosed, goes beyond health consequences and includes significant economic problems. The absence of symptoms of the disease, their insufficient and non-specific manifestations in the early stages of the disease lead to insufficient and untimely diagnosis.
COPD is a disease associated with changes in the airways of the lungs caused by an inflammatory reaction of macrophages, eosinophils, neutrophils, epithelial cells, which begins long before the first clinical symptoms of the disease appear. Detection of changes in specific biomarkers in body fluids, such as oral fluid, blood serum, sputum can be used for early detection of the disease, when there is still time to delay, prevent or reverse damage to organs and tissues, and at the early stages of COPD formation to monitor the patient’s condition. The search for the optimal way to solve this problem was the reason for this literature review.
Keywords: COPD, pre-COPD, biomarkers, prognosis.
References
1. Global strategy for prevention, diagnosis and management of COPD: 2024 Report. Global Initiative for Chronic Obstructive Lung Disease: [website]. URL: https://goldcopd.org/2024- gold-report/ [Accessed 14th January 2025].
2. Lu HH, Zeng HH, Chen Y. Early chronic obstructive pulmonary disease: A new perspective. Chronic Diseases and Translational Medicine. 2021 Apr;7(2):79-87. doi: http://dx.doi.org/10.1016/j.cdtm.2021.02.003
3. Boers E, Barrett M, Su JG, Benjafield AV, Sinha S, Kaye L, et al. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. JAMA Network Open. 2023 Dec;6(12):e2346598. doi: http://dx.doi.org/10.1001/jamanetworkopen.2023.46598
4. Vaezi A, Mirsaeidi M. Proposing the potential of utilizing the CAT score for early detection of COPD in asymptomatic patients, shifting towards a patient-centered approach: A review. Medicine (Baltimore). 2024 Apr 12;103(15):e37715. doi: http://dx.doi.org/10.1097/MD.0000000000037715
5. Halbert CH, Armstrong K, Gandy OH, Shaker L. Racial differences in trust in health care providers. Archives of Internal Medicine. 2006 Apr 24;166(8):896-901. doi: http://dx.doi.org/10.1001/archinte.166.8.896
6. Shevtsova VI, Zuykova AA, Pashkov AN. Early detection of chronic obstructive pulmonary disease - a vector for biomarkers. Arkhiv” Vnutrennei Meditsiny. 2016;6(4):47-52. (In Russ.). doi: http://dx.doi.org/10.20514/2226-6704-2016-6-4-47-52
7. Murphy DE, Panos RJ. Diagnosis of COPD and clinical course in patients with unrecognized airflow limitation. International Journal of Chronic Obstructive Pulmonary Disease. 2013:8:199-208. doi: http://dx.doi.org/10.2147/COPD.S39555
8. Cooper C, Katona C, Livingston G. Validity and reliability of the brief cope in carers of people with dementia: the LASER-AD Study. The Journal of Nervous and Mental Disease. 2008 Nov;196(11):838-843. doi: http://dx.doi.org/10.1097/NMD.0b013e31818b504c
9. López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016 Jan;21(1):14-23. doi: http://dx.doi.org/10.1111/resp.12660
10. Postma DF, van Werkhoven CH, van Elden LJR, Thijsen SFT, Hoepelman AIM, Kluytmans JAJW, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. The New England Journal of Medicine. 2015 Apr 2;372(14):1312-1323. doi: http://dx.doi.org/10.1056/NEJMoa1406330
11. Enright SJ, Unnithan VB, Heward C, Withnall L, Davies DH. Effect of high-intensity inspiratory muscle training on lung volumes, diaphragm thickness, and exercise capacity in subjects who are healthy. Physical Therapy. 2006 Mar;86(3):345-354.
12. Kranenburg AR, Willems-Widyastuti A, MooriWJ, Sterk PJ, Alagappan VK, de Boer WI, et al. Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. American Journal of Clinical Pathology. 2006 Nov;126(5):725-35. doi: http://dx.doi.org/10.1309/jc477fael1ykv54w
13. Ishchenko OV, Yupatova TG. Effect of aqueous extract of cigarette tobacco on lysozyme and lactoferrin levels in oral fluid. Immunopatologija Allergologija Infektologija. 2017;(4):37-43. (In Russ.). doi: http://dx.doi.org/10.14427/jipai.2017.4.37
14. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Archives of Internal Medicine. 2000 Sep;160(17):2653-2658. doi: http://dx.doi.org/10.1001/archinte.160.17.2653
15. Rutten EP, Calverley PMA, Casaburi R, Agusti A, Bakke P, Celli B, et al. Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes? Annals of Nutrition and Metabolism. 2013;63(3):239-247. doi: http://dx.doi.org/10.1159/000353211
16. Koutsokera A, Kostikas K, Nicod LP, Fitting JW. Pulmonary biomarkers in COPD exacerbations: a systematic review. Respiratory Research. 2013 Oct 21;14(1):111. doi: http://dx.doi.org/10.1186/1465-9921-14-111
17. Brightling CE, Saha S, Hollins F. Interleukin-13: prospects for new treatments. Clinical and Experimental Allergy. 2010 Jan;40(1):42-49. doi: http://dx.doi.org/10.1111/j.1365-2222.2009.03383.x
18. Saha S, Mistry V, Siva R, Parker D, May R, Bradding P, et al. Induced sputum and bronchial mucosal expression of interleukin-13 is not increased in chronic obstructive pulmonary disease. Allergy. 2008 Sep;63(9):1239-1243. doi: http://dx.doi.org/10.1111/j.1398-9995.2008.01717.x
19. Barceló B, Pons J, Fuster A, Sauleda J, Noguera A, Ferrer JM, et al. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clinical and Experimental Immunology. 2006 Sep;145(3):474-479. doi: http://dx.doi.org/10.1111/j.1365-2249.2006.03167.x
20. Boutten A, Bonay M, Laribe S, Leseche G, Castier Y, Leçon-Malas V, et al. Decreased expression of interleukin 13 in human lung emphysema. Thorax. Thorax. 2004 Oct;59(10):850-854. doi: http://dx.doi.org/10.1136/thx.2004.025247
21. Hoshino T, Kato S, Oka N, Imaoka H, Kinoshita T, Takei S, et al. Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. American journal of Respiratory and Critical Care Medicine. 2007 Jul;176(1):49-62. doi: http://dx.doi.org/10.1164/rccm.200603-316OC
22. Doyle AD, Mukherjee M, LeSuer WE, Bittner TB, Pasha SM, Frere JJ, et al. Eosinophil-derived IL-13 promotes emphysema. The European Respiratory Journal. 2019 May;53(5):1801291. doi: http://dx.doi.org/10.1183/13993003.01291-2018
23. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. Journal of Autoimmunity. 2010 May;34(3):258-265. doi: http://dx.doi.org/10.1016/j.jaut.2009.12.003
24. Palmer RM, Wilson RF, Hasan AS, Scott DA. Mechanisms of action of environmental factors-tobacco smoking. Journal of Clinical Periodontology. 2005:32 Suppl 6:180-195. doi: http://dx.doi.org/10.1111/j.1600-051X.2005.00786.x
25. Smirnova OV. Induction by cigarette smoke of myeloperoxylase release by leukocytes of patients with chronic obstructive pulmonary disease. Immunopatologija Allergologija Infektologija. 2015;(1):64-70. (In Russ.)
26. Hanstock HG, Edwards JP, Walsh NP. Tear Lactoferrin and Lysozyme as Clinically Relevant Biomarkers of Mucosal Immune Competence. Frontiers in Immunology. 2019 May:10:1178. doi: http://dx.doi.org/10.3389/fimmu.2019.01178
Submitted 02.12.2024
Accepted 11.02.2025
Information about authors:
T.H. Hardziyevich – assistant lecturer of the Chair of Clinical Immunology and Allergology with the course of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University, https://orcid.org/0009-0007-1772-0839,
e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Tatyana H. Hardziyevich;
A.V. Ishchanka – Doctor of Medical Sciences, professor, head of Chair of Clinical Immunology and Allergology with the course of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University, https://orcid.org/0000-0001-8755-7482
